Halozyme Therapeutics, Inc. (HALO) — Analysis Summary
Halozyme Therapeutics, Inc. (HALO) has a market cap of $7.89B with year-over-year revenue growth of +37.6%. Net margin stands at 22.7%. The stock trades at a P/E ratio of 22.6.
Key Takeaways
- Revenue changed +37.6% year-over-year
- Net margin of 22.7%
- P/E ratio of 22.6
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, HALO posted revenue growth of +37.6% and trades at a P/E of 22.6.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.